Abstract: The invention relates to a novel process of amalodipine benzenesulphonate of formula (I) by reacting a new 2-[/2-carboxy-benzoyl)-aminoethoxy/methyl/]-4-(2-chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-di-hydropyridine derivative of general formula (II) wherein X represents hydrogen or alkali metal or alkali earth metal or quaternary ammonium—with benzenesulphonic acid.

Abstract: A kit to alleviate tobacco-smoking withdrawal symptoms in a patient is disclosed which comprises: (a) a therapeutically effective amount of nicotine, at least one active nicotine metabolite, a combination of nicotine and an active nicotine metabolite, or an azapirone, or a pharmaceutically acceptable salt thereof; (b) a transdermal delivery system consisting essentially of a bupropion base in a therapeutically effective amount; and (c) a packaging material surrounding (a) and (b).

Abstract: The invention relates to a new process for the synthesis of 17&bgr;-hydroxy-17&agr;-methyl-2-oxa-5&agr;-androstane-3-one of formula (I).

Abstract: Ammonia is recovered from waste water containing NH3, at least one acid gas (CO2, H2S) and inert gases. Firstly, the waste water is passed through a pretreatment column and then, at least in part, into a total stripping column. The top product from the total stripping column is cooled in a condenser, and an aqueous NH3-containing condensate coming from the condenser is fed to an NH3 stripping column. The top product from the NH3 stripping column is brought into direct contact with circulating aqueous NH3-containing condensate in a wash column, and NH3 is recovered from the top product from the wash column. Some of the bottom product from the wash column is fed back into the NH3 stripping column. The temperature in the bottom region of the pretreatment column is set to from less than 30 to 200° C., a sub-stream of the waste water is introduced into the upper region of the pretreatment column, and a second sub-stream of the waste water is fed into the pretreatment column below the first sub-stream.

Abstract: The invention concerns a two-component coating agent with a) a water dilutable binder component of a polyester resin base and/or polyacrylate resin base, whereby the polyester and/or polyacrylate resin has a content of hydroxyl groups of 2.5 to 8% by weight OH and b) an aqueous organic polyisocyanate component of at least one polyisocyanate with free isocyanate groups which is prepared ready for use for a limited time by the stirring of the polyisocyanate component b) into the binder component a) and hardens by cross-linking of the binder component with the polyisocyanate to the binder components according to the invention are provided as aqueous emulsions of a water insoluble carboxylate-free and sulfanate-free polyester resin and/or polyacrylate resin, whereby the emulsion is produced with the aid of an emulsifier added to the polyester or polyacrylate resin. The subject of the invention is, further, a process for producing the water-dilutable binder component a).

Abstract: A catalyst for reacting SO2 with molecular oxygen to form SO3 is suited for a continuous operation at temperatures of 700° C. and above, when the same consists of a carrier and an active component connected with the carrier, the active component consists of 10 to 80 wt-% iron, the carrier has a BET surface of 100 to 2000 m2/g and an SiO2 content of at least 90 wt-%, and the weight ratio carrier:active component is 1:1 to 100:1.

Abstract: A vaccine is disclosed for the prophylaxis against pathogenic development of atherosclerotic plaque in a mammalian subject susceptible thereto which consists essentially of a multiplicity of killed whole-virus strains, selected from the group consisting of: Herpes Simplex Virus 1; Herpes Simplex Virus 2; Herpes Simplex Virus 6; Human Cytomegalovirus; and Epstein-Barr Virus; in combination with a pharmaceutically acceptable inert vaccine carrier or diluent.

Abstract: The present invention relates to a process of recovering monomeric esters of substituted or unsubstituted acrylic acid from polymer material having corresponding structural units by depolymerization by means of a fine-grained heat-transfer medium which is maintained above the depolymerization temperature of the polymer material. In a reactor, the polymer material is brought in contact with hot, mechanically fluidized heat-transfer medium. The resulting vapors are withdrawn and condensed, where the hot heat-transfer medium is continuously supplied at one end of the reactor, and cooled heat-transfer medium is discharged at the other end.

Abstract: Complexes of deprotonated hyaluronic acid with 3d metal ions of the 4th period of the Periodic Table and compositions containing these complexes as active ingredients or carriers. A process for the preparation of the complexes and compositions (pharmaceutical and cosmetic compositions) containing these complexes as active ingredients are disclosed in which zinc or cobalt (II) hyaluronate is preferably used as active ingredient.

Abstract: The invention relates to a process for production of zeolites from raw materials with alkali alumino-hydrosilicate content comprising converting the alkali alumino-hydrosilicate content of the raw material into an amorphous state by acidic treatment, separating the intermediate amorphous solid material from the liquid phase and optionally purifying same, re-suspending it in water, alkalizing the suspension, followed by forming a slurry of the composition corresponding to the type of zeolite to be manufactured optionally by blending it with components containing SiO2, and/or Al2O3 and/or Na2O, followed by crystallization by method known per se after optionally adding crystal nuclei and/or aging of the synthesis slurry and separating the obtained zeolite product.

Abstract: The invention relates to a new process for the synthesis of 17&bgr;-hydroxy-17&agr;-methyl-1,3-seco-2-nor-5&agr;-androstane-3-acid derivatives of formula (I) wherein the meaning of Z is carboxyl or formyl group and to the new secoindoxylidene carboxylic acid derivatives of formula (II) wherein R1 and R2 independently are C1-C4 alkyl or alkoxy group, hydrogen or halogen atom—which are intermediates for preparing the compounds of formula (I). The 17&bgr;-hydroxy-17&agr;-methyl-1,3-seco-2-nor-5&agr;-androstane-3-acid derivatives of formula (I) are intermediates in the synthesis of oxandrolon (17&bgr;-hydroxy-17&agr;-methyl-2-oxa-5&agr;-androstane-3-one), which is used as anabolic in therapy.

Abstract: A method of partial area-specific-fertilization of plants which, under natural light during the fertilizer application, the chlorophyll content of the plants is ascertained by means of sensors by optical reflection measurement in the visible and near infrared spectral range, the chlorophyll content is registered and from the chlorophyll content a measurement of the nutrient state of the plant is determined and from the nutrient state of the plants a computer controls the fertilizer quantity to be applied, characterized in that the reflection measurements are taken simultaneously as inclined measurements with respect to the nadir with measurement devices oriented oppositely to one another free from shadows with light guides an the influence of the solar azimuth angle is eliminated by detecting the noise signals from all measurement directions.

Abstract: The invention relates to a method for increasing the gene expression of saccharose synthase. To this end the invention provides for the expression of the saccharose synthase gene to be placed under the control of a proton-ATPase promoter. According to a preferred version of the invention gene expression of the saccharose synthase is also increased by increasing the number of copies of the saccharose synthase gene and of the proton-ATPase promoter.

Abstract: A method is disclosed for encapsulating solder metal powders and the microencapsulated metal solder in such a way that the metal powder is reliably protected from external oxidizing influences and the capsule only releases the metal powder as a result of the influence of temperature, without the influence of soldering flux.

Abstract: A method of treating dysphoria or depression is disclosed in a patient which comprises the step of administering orally or non-orally to said patient, a therapeutically effective amount of 1-threo-methylphenidate or a pharmaceutically acceptable acid addition salt thereof.

Abstract: The invention relates to an active substance inhibiting tumorous proliferation in ectoderm derived tissues and to a composition containing such substance.

Abstract: Novel solid phase reaction supports are disclosed. The solid phase reaction supports include (a) a solid phase carrier having a multiplicity of NH2 functional groups; (b) a coupling compound covalently bonded to an NH2 group of the solid phase carrier; and (c) a receptor compound coupled to the solid phase carrier through the coupling compound. The coupling compound is preferably ascorbic acid, dehydroascorbic acid or a diketo compound structurally similar to ascorbic acid or dehydroascorbic acid. The solid phase carrier is preferably made of cellulose.

Abstract: Novel solid phase reaction supports are disclosed. The solid phase reaction supports include (a) a solid phase carrier having a multiplicity of NH2 functional groups of the Formula (I): in which R1 and R2 are each H, or R1 is H and R2 is an alkyl or acyl substituent with a degree of substitution ≦1 or R1 is an alkyl or acyl substituent with a degree of substitution ≦1, and R2 is H, or R1 and R2 are each a substituent with a degree of substitution ≦2 and R3 is an aromatic substituent containing at least one free amino group having a substitution degree ≦1; (b) a coupling compound covalently bonded to an NH2 group of the solid phase carrier; and (c) a receptor compound coupled to the solid phase carrier through the coupling compound.

Abstract: The invention relates to pharmaceutical compositions of antimicrobial effect as well as a process for the preparation thereof. The pharmaceutical compositions of the invention comprise zinc or cobalt hyaluronate associate (complex) as active ingredient in admixture with a carrier and/or other additives commonly used in the pharmaceutical industry.

Abstract: A method is disclosed of preventing retinopathy of prematurity in a prematurely born neonate susceptible to developing retinopathy of prematurity, which comprises the step of parenterally administering to said prematurely born neonate, a therapeutically effective amount of a water-soluble, pharmaceutically effective salt of ibuprofen as an active ingredient to promote retinal and choroidal blood flow autoregulation in said neonate.